- Home
- HUSA vs CTNM Comparison
HUSA vs CTNM Comparison
Compare HUSA & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HUSA
- CTNM
- Stock Information
- Founded
- HUSA N/A
- CTNM 2009
- Country
- HUSA United States
- CTNM United States
- Employees
- HUSA N/A
- CTNM N/A
- Industry
- HUSA Oil & Gas Production
- CTNM
- Sector
- HUSA Energy
- CTNM
- Exchange
- HUSA Nasdaq
- CTNM Nasdaq
- Market Cap
- HUSA 339.8M
- CTNM 328.1M
- IPO Year
- HUSA N/A
- CTNM 2024
- Fundamental
- Price
- HUSA $5.29
- CTNM $11.57
- Analyst Decision
- HUSA
- CTNM Strong Buy
- Analyst Count
- HUSA 0
- CTNM 5
- Target Price
- HUSA N/A
- CTNM $22.20
- AVG Volume (30 Days)
- HUSA 229.8K
- CTNM 106.5K
- Earning Date
- HUSA 11-14-2025
- CTNM 10-30-2025
- Dividend Yield
- HUSA N/A
- CTNM N/A
- EPS Growth
- HUSA N/A
- CTNM N/A
- EPS
- HUSA N/A
- CTNM N/A
- Revenue
- HUSA N/A
- CTNM N/A
- Revenue This Year
- HUSA N/A
- CTNM N/A
- Revenue Next Year
- HUSA N/A
- CTNM N/A
- P/E Ratio
- HUSA N/A
- CTNM N/A
- Revenue Growth
- HUSA N/A
- CTNM N/A
- 52 Week Low
- HUSA $4.79
- CTNM $3.35
- 52 Week High
- HUSA $12.70
- CTNM $17.49
- Technical
- Relative Strength Index (RSI)
- HUSA 45.76
- CTNM 56.08
- Support Level
- HUSA $4.91
- CTNM $10.07
- Resistance Level
- HUSA $5.63
- CTNM $11.75
- Average True Range (ATR)
- HUSA 0.39
- CTNM 0.80
- MACD
- HUSA 0.07
- CTNM 0.05
- Stochastic Oscillator
- HUSA 47.52
- CTNM 89.29
About HUSA Houston American Energy Corporation
Houston American Energy Corp is an independent oil and gas company focused on the development, exploration, exploitation, acquisition, and production of natural gas and crude oil properties. Its properties, and operations, are in the U.S. Permian Basin, the U.S. Gulf Coast region, particularly Louisiana, and the South American country of Colombia. Geographically, the company currently has operations in two geographical areas, the United States, from where it derives maximum revenue, and Colombia.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.